5:32 PM
 | 
Dec 19, 2012
 |  BC Extra  |  Clinical News

Idera's IMO-3100 misses Phase IIa psoriasis endpoint

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) said once-weekly subcutaneous IMO-3100 for four weeks with a four week follow-up period missed the primary endpoint in a Phase IIa trial to treat moderate to severe...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >